Scinai Immunotherapeutics (SCNI) Cash from Investing Activities (2018 - 2026)

Scinai Immunotherapeutics (SCNI) has 9 years of Cash from Investing Activities data on file, last reported at $2.7 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities rose 30433.33% year-over-year to $2.7 million; the trailing twelve-month figure through Mar 2026 stood at $2.7 million (up 54340.0% YoY), and the FY2025 full-year result was -$24000.0, down 100.0% from the prior year.
• Cash from Investing Activities grew to $2.7 million in Q1 2026, from -$21000.0 in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $2.7 million in Q1 2026 to a low of -$521000.0 in Q1 2022.
• A 5-year average of $75466.7 and a median of -$21000.0 in 2025 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities sank 13125.0% in 2022 and soared 30433.33% in 2026, its largest moves.
• Tracing SCNI's Cash from Investing Activities over 5 years: stood at -$270000.0 in 2022, then climbed by 13.33% to -$234000.0 in 2023, then soared by 89.74% to -$24000.0 in 2024, then advanced by 12.5% to -$21000.0 in 2025, then soared by 13185.71% to $2.7 million in 2026.
• Business Quant data shows SCNI's Cash from Investing Activities at $2.7 million in Q1 2026, -$21000.0 in Q2 2025, and $9000.0 in Q1 2025.